| . | Controls . | HIV-2-LV . | HIV-2-HV . | HIV-1 . | P Valuea . |
|---|---|---|---|---|---|
| N | 10 | 10 | 7 | 10 | |
| Gender (F:M) | 7:3 | 8:2 | 7:0 | 6:4 | |
| Age (years) | 26.5 (23–35) | 41.0 (38–46) | 38.0 (35–52) | 42.0 (29–55) | <.005 |
| Viral load (copies/mL) | N/A | <100 | 2834 (2028–121 199) | 186 347 (53 249–486 378) | <.001 |
| CD4 count (cells/µL) | 872 (747–1286) | 946 (681–1019) | 761 (530–980) | 780 (575–854) | .263 |
| CD4% | 40.5 (38–45) | 35.5 (32–45) | 37.0 (32–39) | 27.5 (35–21) | .004 |
| CD8 count (cells/µL) | 689 (456–774) | 750 (549–1047) | 637 (427–804) | 1076 (926–1600) | .010 |
| Weight (kg) | 63.7 (61.4–84.1) | 71.8 (62.3–80.7) | 66.4 (58.7–96.2) | 54.8 (50.0–63.2) | .023 |
| Time in cohort (years) | N/A | 11.8 (4.1–14.8) | 5.7 (1.0–11.7) | 1.3 (0.9–5.5) | .020 |
| . | Controls . | HIV-2-LV . | HIV-2-HV . | HIV-1 . | P Valuea . |
|---|---|---|---|---|---|
| N | 10 | 10 | 7 | 10 | |
| Gender (F:M) | 7:3 | 8:2 | 7:0 | 6:4 | |
| Age (years) | 26.5 (23–35) | 41.0 (38–46) | 38.0 (35–52) | 42.0 (29–55) | <.005 |
| Viral load (copies/mL) | N/A | <100 | 2834 (2028–121 199) | 186 347 (53 249–486 378) | <.001 |
| CD4 count (cells/µL) | 872 (747–1286) | 946 (681–1019) | 761 (530–980) | 780 (575–854) | .263 |
| CD4% | 40.5 (38–45) | 35.5 (32–45) | 37.0 (32–39) | 27.5 (35–21) | .004 |
| CD8 count (cells/µL) | 689 (456–774) | 750 (549–1047) | 637 (427–804) | 1076 (926–1600) | .010 |
| Weight (kg) | 63.7 (61.4–84.1) | 71.8 (62.3–80.7) | 66.4 (58.7–96.2) | 54.8 (50.0–63.2) | .023 |
| Time in cohort (years) | N/A | 11.8 (4.1–14.8) | 5.7 (1.0–11.7) | 1.3 (0.9–5.5) | .020 |
Values are median (IQR).
Abbreviations: ANOVA, analysis of variance; HIV, human immunodeficiency virus; HIV-2-HV, HIV-2 infected with high viral load (>1000 copies/mL); HIV-2-LV, HIV-2 infected with low viral load (<100 copies/mL); IQR, interquartile range; N/A, not applicable.
aP represents comparison of groups by ANOVA (Kruskal–Wallis).
| . | Controls . | HIV-2-LV . | HIV-2-HV . | HIV-1 . | P Valuea . |
|---|---|---|---|---|---|
| N | 10 | 10 | 7 | 10 | |
| Gender (F:M) | 7:3 | 8:2 | 7:0 | 6:4 | |
| Age (years) | 26.5 (23–35) | 41.0 (38–46) | 38.0 (35–52) | 42.0 (29–55) | <.005 |
| Viral load (copies/mL) | N/A | <100 | 2834 (2028–121 199) | 186 347 (53 249–486 378) | <.001 |
| CD4 count (cells/µL) | 872 (747–1286) | 946 (681–1019) | 761 (530–980) | 780 (575–854) | .263 |
| CD4% | 40.5 (38–45) | 35.5 (32–45) | 37.0 (32–39) | 27.5 (35–21) | .004 |
| CD8 count (cells/µL) | 689 (456–774) | 750 (549–1047) | 637 (427–804) | 1076 (926–1600) | .010 |
| Weight (kg) | 63.7 (61.4–84.1) | 71.8 (62.3–80.7) | 66.4 (58.7–96.2) | 54.8 (50.0–63.2) | .023 |
| Time in cohort (years) | N/A | 11.8 (4.1–14.8) | 5.7 (1.0–11.7) | 1.3 (0.9–5.5) | .020 |
| . | Controls . | HIV-2-LV . | HIV-2-HV . | HIV-1 . | P Valuea . |
|---|---|---|---|---|---|
| N | 10 | 10 | 7 | 10 | |
| Gender (F:M) | 7:3 | 8:2 | 7:0 | 6:4 | |
| Age (years) | 26.5 (23–35) | 41.0 (38–46) | 38.0 (35–52) | 42.0 (29–55) | <.005 |
| Viral load (copies/mL) | N/A | <100 | 2834 (2028–121 199) | 186 347 (53 249–486 378) | <.001 |
| CD4 count (cells/µL) | 872 (747–1286) | 946 (681–1019) | 761 (530–980) | 780 (575–854) | .263 |
| CD4% | 40.5 (38–45) | 35.5 (32–45) | 37.0 (32–39) | 27.5 (35–21) | .004 |
| CD8 count (cells/µL) | 689 (456–774) | 750 (549–1047) | 637 (427–804) | 1076 (926–1600) | .010 |
| Weight (kg) | 63.7 (61.4–84.1) | 71.8 (62.3–80.7) | 66.4 (58.7–96.2) | 54.8 (50.0–63.2) | .023 |
| Time in cohort (years) | N/A | 11.8 (4.1–14.8) | 5.7 (1.0–11.7) | 1.3 (0.9–5.5) | .020 |
Values are median (IQR).
Abbreviations: ANOVA, analysis of variance; HIV, human immunodeficiency virus; HIV-2-HV, HIV-2 infected with high viral load (>1000 copies/mL); HIV-2-LV, HIV-2 infected with low viral load (<100 copies/mL); IQR, interquartile range; N/A, not applicable.
aP represents comparison of groups by ANOVA (Kruskal–Wallis).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
